Q4 2025 HLS Therapeutics Inc Earnings Call Transcript
Key Points
- HLS Therapeutics Inc (HLTRF) achieved 18% growth in adjusted EBITDA for the full year 2025, reflecting a balanced approach to driving product performance while optimizing spend.
- Vascepa unit demand grew 23% for the year, marking a positive contribution to adjusted EBITDA for the first time.
- The company successfully launched NILEMDO in Canada, with plans for a full commercial launch in early April 2026.
- HLS Therapeutics Inc (HLTRF) reduced net debt by 23% in 2025, improving cash flow and strengthening the balance sheet.
- The company anticipates strong margins from NILEMDO and NEXLIZET, leveraging existing cardiovascular infrastructure for increased profitability.
- Total revenue for the full year 2025 was slightly down at $55.5 million compared to $56.6 million in 2024.
- Royalty revenue decreased to $0.7 million for the full year, down from $1.5 million in 2024.
- The company faced revenue pressure in Ontario due to new GPO arrangements and increased competitive activity.
- HLS Therapeutics Inc (HLTRF) expects some further revenue pressure from 2025 renegotiations in Ontario.
- The 2026 financial guidance reflects relatively flat adjusted EBITDA compared to 2025, with conservative sales expectations for NILEMDO.
Good morning, and welcome to the Q4 and fiscal 2025 financial results conference call for HLS Therapeutics. (Operator Instructions). This call is being recorded on Thursday, March 12, 2026. At this time, I would like to turn the call over to David Mason, Investor Relations, for the introductory remarks.
Thank you, Joelle. Good morning, everyone, and thanks for joining us today. With me on the call is Craig Millian, Chief Executive Officer; John Hanna, Chief Financial Officer; and Brian Walsh, Chief Commercial Officer.
Earlier this morning, we issued a news release announcing the financial results for the 3 months and 12 months ended December 31, 2025. This news release, along with our MD&A and financial statements is available on our website and on SEDAR+. Please note that slides accompanying today's call can be viewed via the webcast, a link to which is available in our earnings release and on our website on the Events page.
Certain matters discussed in today's conference call or
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
